All
Addressing Learning Curves in Rare NSCLC Subtypes and Targeted Therapy Use: Jorge Nieva, MD
September 1st 2025Jorge Nieva, MD, explores the challenges of translating biomarker testing into treatment decisions for non–small cell lung cancer (NSCLC), the role of repeat testing in detecting resistance mutations, and the importance of equitable access to molecular diagnostics in value-based care settings.
Read More
Overcoming Barriers to Molecular Testing in NSCLC Care: Jorge Nieva, MD
August 29th 2025Jorge Nieva, MD, highlights the critical role of molecular testing in non–small cell lung cancer (NSCLC) care, while addressing barriers such as limited tissue samples, delayed turnaround times, and the need for faster, more accessible diagnostic technologies.
Read More
Improving Clinical Trial Diversity Through Language-Inclusive Approaches: Daniel Virnich, MD
August 29th 2025Daniel Virnich, MD, highlights the need for proactive social determinants of health screening, language-inclusive clinical trial practices, value-based treatment decisions, and policy reforms to improve equitable access to cancer care.
Read More
Clinical Considerations for Immunotherapy Sequencing in NSCLC: Lauren Antrim, MD
August 29th 2025Lauren Antrim, MD, of City of Hope Cancer Center Duarte, emphasized the need for more evidence to guide optimal immunotherapy duration and sequencing in in non–small cell lung cancer (NSCLC), highlighting ongoing trials and the potential role of ctDNA in tailoring treatment strategies.
Read More
Balancing Safety, Cost, and Duration in Immunotherapy for NSCLC: Lauren Antrim, MD
August 28th 2025Lauren Antrim, MD, emphasized the need to balance safety, efficacy, and financial considerations when managing immune checkpoint inhibitors in NSCLC, underscoring the importance of patient-centered discussions and ongoing trials to refine treatment duration strategies.
Read More
Patient Engagement Can Help Drive More Comprehensive NSCLC Testing: Julia Rotow, MD
August 26th 2025The definition of comprehensive non-small cell lung cancer (NSCLC) testing is rapidly evolving with new biomarkers and therapies, according to Julia Rotow, MD, creating added challenges for community practices.
Read More
Cutting-Edge and Basic Treatments Can Work in Tandem to Address NSCLC: Frank Weinberg, MD, PhD
August 26th 2025Cutting-edge therapies can help move the treatment landscape forward, but basic treatment and prevention, such as smoking cessation, are still valuable means of addressing non–small cell lung cancer (NSCLC).
Read More
Addressing Financial and Socioeconomic Barriers to Precision NSCLC Care: Jonathan Thompson, MD, MS
August 25th 2025Jonathan Thompson, MD, MS, explains how financial, insurance, and socioeconomic barriers limit equitable access to biomarker testing and advanced therapies, underscoring the need for provider advocacy and systemic support.
Read More
Weighing Relapse Risk Against Benefit in Advanced NSCLC Immunotherapy: Jonathan Thompson, MD, MS
August 22nd 2025In advanced non–small cell lung cancer (NSCLC), discontinuing immunotherapy after 2 years can maintain durable responses while reducing financial and toxicity burdens, with decisions guided by residual disease testing and shared decision-making, explained Jonathan Thompson, MD, MS.
Read More
CAR T and Bispecifics Pose Different Challenges in Blood Cancer Treatment: Ravi Vij, MD, MBA
August 21st 2025Ravi Vij, MD, MBA, discusses the logistical differences between administering CAR T-cell therapy and bispecific antibodies, and how emerging CAR T technologies could affect patient access.
Read More
Navigating Perioperative Immunotherapy Decisions in Lung Cancer Care: Jonathan Thompson, MD, MS
August 21st 2025Jonathan Thompson, MD, MS, explains that adjuvant immunotherapy benefits patients with early-stage lung cancer with incomplete neoadjuvant response, while treatment decisions in the adjuvant setting must weigh efficacy, toxicity, and limited evidence.
Read More
Jonathan Thompson, MD, MS, highlighted that reducing delays in molecular testing and treatment initiation is critical for improving lung cancer outcomes, and that clinical trial data suggest immunotherapy duration can often be safely de-escalated in patients who achieve a complete pathologic response.
Read More
Biomarker Testing, Perioperative Treatment in NSCLC: Frank Weinberg, MD, PhD
August 20th 2025A panel held during the Institute for Value-Based Medicine event in Chicago on August 14, 2025, included discussions of access to biomarker testing and perioperative treatment in patients with non–small cell lung cancer (NSCLC).
Read More
Expanding the Role of NGS and Retesting in Early and Refractory NSCLC: Jonathan Thompson, MD, MS
August 19th 2025Jonathan Thompson, MD, MS, emphasized that broader molecular testing in early-stage non–small cell lung cancer (NSCLC) is essential to guide perioperative treatment decisions, while selective retesting at progression can identify resistance mutations or new targets to optimize value-based care.
Read More
Embedding Reflex Biomarker Testing to Advance Precision Lung Cancer Care: Jonathan Thompson, MD, MS
August 18th 2025Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision therapy in lung cancer and to address persistent disparities in timely, equitable access to care.
Read More
Clayton Irvine, PharmD, MBA, MS, discusses how pharmacists are essential to advancing payer–provider collaboration in value-based care by shaping formularies, standardizing drug reviews, leveraging real-world evidence, and leading pilot programs to optimize patient outcomes and cost-effectiveness.
Read More
Clayton Irvine, PharmD, MBA, MS, emphasized that optimizing value-based access to cell and gene therapies requires standardized care protocols, coordinated transitions between care settings, careful evaluation of prior authorization and financial assistance options, and formulary decisions that balance clinical outcomes with both direct and indirect costs to patients and institutions.
Read More
Considerations for Patient Monitoring Following CAR T and Bispecific Administration: Amir Fathi, MD
August 14th 2025Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients and their treatment team and key distinct toxicities that require vigilance.
Read More
Jason Bergsbaken, PharmD, MBA, BCOP, explains the value of pharmacist involvement in precision molecular tumor boards and end-of-life care discussions, highlighting their role in ensuring evidence-based therapy selection, patient-specific recommendations, and shared decision-making that aligns treatment with individual goals.
Read More
Clayton Irvine, PharmD, MBA, MS, discusses strategies to address payer-driven biosimilar and prior authorization challenges through integrated digital solutions, while advocating for flexible, regularly reviewed treatment pathways supported by molecular tumor boards and artificial intelligence to balance standardization with personalized, biomarker-driven oncology care.
Read More
Clayton Irvine, PharmD, MBA, MS, explains that leveraging high-quality, real-world data; cross-institutional collaboration; standardized care pathways; advanced technologies; and integrated academic–community oncology partnerships can improve treatment decision-making, reduce financial toxicity, address drug shortages, and optimize infusion center efficiency.
Read More